건강한 자원자에서 Udenafil 100 mg 제형 및 200 mg 제형 간 약동학적 특성 비교 (Comparison of the Pharmacokinetics Between Udenafil 100 mg tablets and 200 mg tablets in Healthy Volunteers)

서지정보

· 발행기관 : 대한임상약리학회
· 수록지 정보 : Translational and Clinical Pharmacology / 16권 / 1호 / 45 ~ 52페이지
· 저자명 : 신광희, 김정렬, 조주연, 윤서현, 신현숙, 장인진, 신상구, 유경상

초록

Background: Udenafil is a new phosphodiesterase (PDE) 5 inhibitor for the treatment of erectile dysfunction. The safety and efficacy of udenafil were shown in clinical studies, and two dosing regimens (100 mg and 200 mg) received marketing approval for 100 mg tablets. In this study, we compared the pharmacokinetics between udenafil 100 mg tablets and 200 mg tablets.
Methods: The pharmacokinetic characteristics of the 200 mg strength formulation were compared with the 100 mg strength formulation in an open-labeled, randomized, two-way crossover study in 20 healthy male volunteers. A group of 9 subjects were dosed one udenafil 200 mg tablet and administered
two 100 mg tablets one week later. Another group of 11 subjects were dosed in the opposite sequence.
As an outcome, plasma udenafil concentration-time profiles were obtained. Pharmacokinetic characteristics were analyzed using the 90% confidence intervals of the geometric mean ratios for
maximum plasma concentration (Cmax) and the area under the concentration-time curve from time zero
to infinity (AUCinf).
Results: The two dosage formulations showed similar concentration-time profiles. The geometric mean
ratio of Cmax of udenafil 200 mg formulation to 100 mg formulation was 0.94 and the 90% confidence
interval was 0.86-1.02. The geometric mean ratio of AUCinf was 0.93 and the 90% confidence interval
for the two regimens was 0.87 - 1.00.
Conclusion: The 200 mg tablets showed similar pharmacokinetic characteristics compared to the 100
mg tablets as judged from the 90% confidence intervals of the geometric mean ratio for Cmax and
AUCinf that were both within a range of log 0.80 - log 1.25.

영어초록

Background: Udenafil is a new phosphodiesterase (PDE) 5 inhibitor for the treatment of erectile dysfunction. The safety and efficacy of udenafil were shown in clinical studies, and two dosing regimens (100 mg and 200 mg) received marketing approval for 100 mg tablets. In this study, we compared the pharmacokinetics between udenafil 100 mg tablets and 200 mg tablets.
Methods: The pharmacokinetic characteristics of the 200 mg strength formulation were compared with the 100 mg strength formulation in an open-labeled, randomized, two-way crossover study in 20 healthy male volunteers. A group of 9 subjects were dosed one udenafil 200 mg tablet and administered
two 100 mg tablets one week later. Another group of 11 subjects were dosed in the opposite sequence.
As an outcome, plasma udenafil concentration-time profiles were obtained. Pharmacokinetic characteristics were analyzed using the 90% confidence intervals of the geometric mean ratios for
maximum plasma concentration (Cmax) and the area under the concentration-time curve from time zero
to infinity (AUCinf).
Results: The two dosage formulations showed similar concentration-time profiles. The geometric mean
ratio of Cmax of udenafil 200 mg formulation to 100 mg formulation was 0.94 and the 90% confidence
interval was 0.86-1.02. The geometric mean ratio of AUCinf was 0.93 and the 90% confidence interval
for the two regimens was 0.87 - 1.00.
Conclusion: The 200 mg tablets showed similar pharmacokinetic characteristics compared to the 100
mg tablets as judged from the 90% confidence intervals of the geometric mean ratio for Cmax and
AUCinf that were both within a range of log 0.80 - log 1.25.

참고자료

· 없음